Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

PURCHASE, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)” (doi: 10.1002/alz.71004) has been published in the journal, Alzheimer's & Dementia, the journal of the Alzheimer’s Association. Results from this study were first presented in January 2025 at the International Lewy Body Dementia Conference in Amsterdam. “The Phas ...